Erika Strohmayer, MD
Endocrinology, Diabetes & Metabolism · Trumbull, CTNPI 1306018221
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,765 and has fallen 85.2% since, to $410 in 2025.
Across 233 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$735
- Amgen$528
- Lilly USA, LLC$459
- Sanofi-aventis U.S. LLC$302
- Novo Nordisk$277
- AstraZeneca$255
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,88294%
- Education$2536%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 42 | $735 |
| Amgen | 34 | $528 |
| Lilly USA, LLC | 33 | $459 |
| Sanofi-aventis U.S. LLC | 12 | $302 |
| Novo Nordisk | 19 | $277 |
| AstraZeneca(2 entities) | 17 | $255 |
| Corcept Therapeutics | 7 | $255 |
| Insulet Corporation | 8 | $166 |
| Aytu Biopharma, Inc. | 6 | $113 |
| Pfizer | 8 | $97 |
| Johnson & Johnson | 6 | $96 |
| Radius Health, Inc. | 5 | $94 |
| Amarin Pharma, Inc. | 4 | $83 |
| IBSA Pharma Inc. | 4 | $82 |
| Merck | 5 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Dexcom, Inc. | 1 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Eisai Inc. | 2 | $42 |
| Cequr Corporation | 1 | $41 |
| Vivus LLC | 2 | $36 |
| Bayer | 1 | $31 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Mannkind Corporation | 1 | $27 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Medtronic | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,136 in reported general payments places this provider in the 70th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $199,880 |
| JardianceEmpagliflozin | 69 | $105,105 |
| MounjaroTirzepatide | 74 | $84,217 |
| TrulicityDulaglutide | 34 | $47,363 |
| ProliaDenosumab | 20 | $34,753 |
| TymlosAbaloparatide | 12 | $30,264 |
| FarxigaDapagliflozin Propanediol | 23 | $29,127 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $18,309 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $18,095 |
| JanuviaSitagliptin Phosphate | 11 | $16,703 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $13,642 |
| SynthroidLevothyroxine Sodium | 133 | $13,044 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $12,909 |
| VascepaIcosapent Ethyl | 18 | $11,318 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $10,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $277 | $199,880164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $459 | $131,579108 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $735 | $127,86993 claims |
| MerckJanumet Xr, Januvia | $67 | $35,01226 claims |
| AmgenProlia | $528 | $34,75320 claims |
| Radius Health, Inc.Tymlos | $94 | $30,26412 claims |
| AstraZenecaFarxiga | $255 | $29,12723 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $14 | $5,741520 claims |
| IBSA Pharma Inc.Tirosint | $82 | $5,53220 claims |
| PfizerPremarin | $97 | $4,33415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Trumbull
- Glenn RichTrumbull$210K
- Judith CastilloTrumbull$37K
- Jonathan FillmoreTrumbull$12K
- Joseph RosaTrumbull$8K
- Agnieszka GrochowalskaTrumbull$8K
- Linda WernerTrumbull$3K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.